1. Aleman A, Lincoln TM, Bruggeman R, Melle I, Arends J, Arango C, et al. Treatment of negative symptoms: where do we stand, and where do we go? Schizophr Res 2017; 186: 55-62.
2.
Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: new developments and unanswered research ques-tions. Lancet Psychiatry 2018; 5: 664-677.
3.
Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988; 145: 578-583.
4.
Kirkpatrick B, Galderisi S. Deficit schizophrenia: an update. World Psychiatry 2008; 7: 143-147.
5.
Ahmed AO, Strauss GP, Buchanan RW, Kirkpatrick B, Carpenter WT Jr. Schizophrenia heterogeneity revisited: clinical, cognitive, and psychosocial correlates of statistically-derived negative symptoms subgroups. J Psychiatr Res 2018; 97: 8-15.
6.
Bora E, Akdede BB, Alptekin K. Neurocognitive impairment in deficit and non-deficit schizophrenia: a meta-analysis. Psychol Med 2017; 47: 2401-2413.
7.
Cohen AS, Saperstein AM, Gold JM, Kirkpatrick B, Carpenter WT Jr, Buchanan RW. Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull 2007; 33: 1201-1212.
8.
Tyburski E, Pełka-Wysiecka J, Mak M, Samochowiec A, Bieńkowski P, Samochowiec J. Neuropsychological profile of specific executive dysfunctions in patients with deficit and non-deficit schizophrenia. Front Psychol 2017; 8: e1459. DOI: http://doi.org/10.3389/fpsyg.2017.01459.
9.
Gourevitch R, Abbadi S, Guelfi JD. Quality of life in schizophrenics with and without the deficit syndrome. Eur Psychiatry 2004; 19: 172-174.
10.
Maes M, Vojdani A, Galecki P, Kanchanatawan B. How to construct a bottom-up nomothetic network model and disclose novel nosologi-cal classes by integrating risk resilience and adverse outcome pathways with the phenome of schizophrenia. Brain Sci 2020; 10: e645. DOI: http://doi.org/10.3390/brainsci10090645.
11.
Sum MY, Tay KH, Sengupta S, Sim K. Neurocognitive functioning and quality of life in patients with and without deficit syndrome of schizophrenia. Psychiatry Res 2018; 263: 54-60.
12.
Cai R, Huang C, Ni L, Liu Z, Zhang S, Qiu Y, et al. The motivation and pleasure deficits but not expressivity affects social functioning through cognitive function in male patients with schizophrenia: A structural equation model. Asian J Psychiatr 2023; 85: 103616. DOI: http://doi.org/10.1016/j.ajp.2023.103616.
13.
Liu J, Tian Y, Wei S, Wang W, Wang D, Zhou H, et al. Association of empathy with clinical symptoms and cognitive function in Chinese chronic schizophrenia patients with and without deficit syndrome. Prog Neuropsychopharmacol Biol Psychiatry 2022; 119: e110592. DOI: http://doi.org/10.1016/j.pnpbp.2022.110592.
14.
Antoniades M, Schoeler T, Radua J, Valli I, Allen P, Kempton MJ, et al. Verbal learning and hippocampal dysfunction in schizophrenia: a meta-analysis. Neurosci Biobehav Rev 2018; 86: 166-175.
15.
Doughty OJ, Done DJ. Is semantic memory impaired in schizophrenia? A systematic review and meta-analysis of 91 studies. Cogn Neuro-psychiatry 2009; 14: 473-509.
16.
Pillny M, Krkovic K, Buck L, Lincoln TM. From memories of past experiences to present motivation? A meta-analysis on the association between episodic memory and negative symptoms in people with psychosis. Schizophr Bull 2022; 48: 307-324.
17.
Rouy M, Saliou P, Nalborczyk L, Pereira M, Roux P, Faivre N. Systematic review and meta-analysis of metacognitive abilities in individuals with schizophrenia spectrum disorders. Neurosci Biobehav Rev 2021; 126: 329-337.
18.
Ordemann GJ, Opper J, Davalos D. Prospective memory in schizophrenia: a review. Schizophr Res 2014; 155: 77-89.
19.
Wang Y, Cui J, Chan RCK, Deng Y, Shi H, Hong X, et al. Meta-analysis of prospective memory in schizophrenia: nature, extent, and corre-lates. Schizophr Res 2009; 114: 64-70.
20.
Wang Y, Chan RC, Shum DH. Schizophrenia and prospective memory impairments: a review. Clin Neuropsychol 2018; 32: 836-857.
21.
Zhou FC, Zheng W, Lu L, Wang YY, Ng CH, Ungvari GS, et al. Prospective memory in schizophrenia: a meta-analysis of comparative stud-ies. Schizophr Res 2019; 212: 62-71.
22.
Kanchanatawan B, Tangwongchai S, Supasitthumrong T, Sriswasdi S, Maes M. Episodic memory and delayed recall are significantly more impaired in younger patients with deficit schizophrenia than in elderly patients with amnestic mild cognitive impairment. PLoS One 2018; 13: e0197004. DOI: http://doi.org/10.1371/journal.pone.0197004.
23.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71. DOI: http://doi.org/10.1136/bmj.n71.
24.
Cai R, Zhu Z, Li Y, Fang J, Wu C, Hu Y, et al. Relationship between negative symptoms, cognitive function and social function in schizo-phrenia: new insight from a network analysis. Front Psychiatry 2025; 16: e1623147. DOI: http://doi.org/10.3389/fpsyt.2025.1623147.
25.
Fan L, Yu M, Pinkham A, Zhu Y, Tang X, Wang X, et al. Aberrant large-scale brain modules in deficit and non-deficit schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2022; 113: e110461. DOI: http://doi.org/10.1016/j.pnpbp.2021.110461.
26.
Wang Z, Ling Y, Wang Y, Zhu T, Gao J, Tang X, et al. The role of two factors of negative symptoms and cognition on social functioning in male patients with schizophrenia: a mediator model. Brain Sci 2023; 13: e187. DOI: http://doi.org/10.3390/brainsci13020187.
27.
Yu M, Tang X, Wang X, Zhang X, Zhang X, Sha W, et al. Neurocognitive impairments in deficit and non-deficit schizophrenia and their relationships with symptom dimensions and other clinical variables. PLoS One 2015; 10: e0138357. DOI: http://doi.org/10.1371/journal.pone.0138357.
28.
Yu M, Dai Z, Tang X, Wang X, Zhang X, Sha W, et al. Convergence and divergence of brain network dysfunction in deficit and non-deficit schizophrenia. Schizophr Bull 2017; 43: 1315-1328.
29.
Xie T, Zhang X, Tang X, Zhang H, Yu M, Gong G, et al. Mapping convergent and divergent cortical thinning patterns in patients with deficit and nondeficit schizophrenia. Schizophr Bull 2019; 45: 211-221.
30.
Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment. 4th ed. New York: Oxford University Press; 2004.
31.
Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 3rd ed. New York: Oxford University Press; 2006.
32.
Kmet LM, Lee RC, Cook LS. Standard quality assessment criteria for evaluating primary research papers from a variety of fields. Alberta Heritage Foundation for Medical Research (AHFMR); 2004. Available from: http://www.ihe.ca/files/standard_quality_assessment_criteria_for_evaluating_primary_research_papers_from_a_variety_of_fields.pdf. Accessed August 11, 2025.
33.
Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr. The Schedule for the Deficit Syndrome: an instrument for re-search in schizophrenia. Psychiatry Res 1989; 30: 119-123.
34.
Galderisi S, Mucci A, Dollfus S, Nordentoft M, Falkai P, Kaiser S, et al. EPA guidance on assessment of negative symptoms in schizophrenia. Eur Psychiatry 2021; 64: e23. DOI: http://doi.org/10.1192/j.eurpsy.2021.11.
35.
Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276.
36.
Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799-812.
37.
Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry 1989; 155 (S7): 49-58.
38.
Andreasen NC. Scale for the Assessment of Positive Symptoms. Iowa City: University of Iowa Press; 1984.
39.
Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990; 3: 247-251.
40.
Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, et al. The Brief Negative Symptom Scale: psychometric proper-ties. Schizophr Bull 2011; 37: 300-305.
41.
Dollfus S, Mach C, Morello R. Self-evaluation of negative symptoms: a novel tool to assess negative symptoms. Schizophr Bull 2016; 42: 571-578.
42.
Haro JM, Kamath SA, Ochoa S, Novick D, Rele K, Fargas A, et al. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 2003; 107 (S416): 16-23. DOI: http://doi.org/10.1034/j.1600-0447.107.s416.5.x.
43.
Maroof DA. Statistical Methods in Neuropsychology: Common Procedures Made Comprehensible. New York: Springer; 2012. DOI: http://doi.org/10.1007/978-1-4614-3417-7.
44.
Wechsler D. The Wechsler Memory Scale – Revised. New York: Psychological Corporation; 1987.
45.
Wechsler D. Wechsler Memory Scale. 3rd ed. San Antonio (TX): Psychological Corporation; 1997.
46.
Wechsler D. WAIS-R Manual: Wechsler Adult Intelligence Scale – Revised. New York: Psychological Corporation; 1982.
47.
Cambridge Cognition. CANTAB – Schizophrenia (test batteries). Available from: https://cambridgecognition.com/schizophrenia/ (Ac-cessed: 05.10.2017).
48.
Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): prelimi-nary clinical validity. J Clin Exp Neuropsychol 1998; 20: 310-319.
49.
Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, et al. The MATRICS Consensus Cognitive Battery, part 1: test se-lection, reliability, and validity. Am J Psychiatry 2008; 165: 203-213.
50.
Huang C, Wang J, Zhuang L, Zhu T, Song Y, Sun T, et al. Analysis of the status quo and clinical influencing factors of the social cognitive impairment in deficit schizophrenia. Front Psychiatry 2024; 15: e1470159. DOI: http://doi.org/10.3389/fpsyt.2024.1470159.
51.
Réthelyi JM, Czobor P, Polgár P, Mersich B, Bálint S, Jekkel É, et al. General and domain-specific neurocognitive impairments in deficit and non-deficit schizophrenia. Eur Arch Psychiatry Clin Neurosci 2012; 262: 107-115.
52.
Bryson G, Whelahan HA, Bell M. Memory and executive function impairments in deficit syndrome schizophrenia. Psychiatry Res 2001; 102: 29-37.
53.
Csukly G, Polgár P, Tombor L, Benkovits J, Réthelyi J. Theory of mind impairments in patients with deficit schizophrenia. Compr Psychia-try 2014; 55: 349-356.
54.
Galderisi S, Maj M, Mucci A, Cassano GB, Invernizzi G, Rossi A, et al. Historical, psychopathological, neurological, and neuropsycholog-ical aspects of deficit schizophrenia: a multicenter study. Am J Psychiatry 2002; 159: 983-990.
55.
Galderisi S, Bucci P, Mucci A, Kirkpatrick B, Pini S, Rossi A, et al. Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome. Schizophr Res 2013; 147: 157-162.
56.
Pegoraro LF, Dantas CR, Banzato CEM, Fuentes D. Correlation between insight dimensions and cognitive functions in patients with deficit and nondeficit schizophrenia. Schizophr Res 2013; 147: 91-94.
57.
Seckinger RA, Goudsmit N, Coleman E, Harkavy-Friedman J, Yale S, Rosenfield PJ, et al. Olfactory identification and WAIS-R performance in deficit and nondeficit schizophrenia. Schizophr Res 2004; 69: 55-65.
58.
Fervaha G, Agid O, Foussias G, Siddiqui I, Takeuchi H, Remington G. Neurocognitive impairment in the deficit subtype of schizophrenia. Eur Arch Psychiatry Clin Neurosci 2016; 266: 397-407.
59.
Zaragoza Domingo S, Bobes J, García-Portilla MP, Morralla C; EPICOG-SCH Study Group. Cognitive performance associated to functional outcomes in stable outpatients with schizophrenia. Schizophr Res Cogn 2015; 2: 146-158.
60.
Tang X, Zhou C, Gao J, Duan W, Yu M, Xiao W, et al. Serum BDNF and GDNF in Chinese male patients with deficit schizophrenia and their relationships with neurocognitive dysfunction. BMC Psychiatry 2019; 19: e254. DOI: http://doi.org/10.1186/s12888-019-2231-3.
61.
Chen C, Jiang W, Zhong N, Wu J, Jiang H, Du J, et al. Impaired processing speed and attention in first-episode drug-naive schizophrenia with deficit syndrome. Schizophr Res 2014; 159: 478-484.
62.
Bielecki M, Tyburski E, Plichta P, Mak M, Kucharska-Mazur J, Podwalski P, et al. Executive functions and psychopathology dimensions in deficit and non-deficit schizophrenia. J Clin Med 2023; 12: e1998. DOI: http://doi.org/10.3390/jcm12051998.
63.
Li J, Zhang X, Yang H, Yang M, Sun H. Lack of correlation between hippocampal substructure atrophy and attention dysfunction in deficit schizophrenia. Schizophrenia 2023; 9: e24. DOI: http://doi.org/10.1038/s41537-023-00354-z.
64.
Li J, Zhang X, Wang J, Yang H, Yang M, Gao J, Du X. Thinning of the temporal and insular cortex is associated with negative symptoms and impaired attention in Chinese chronic schizophrenia patients with deficit syndrome. BMC Psychiatry 2025; 25: e411. DOI: http://doi.org/10.1186/s12888-025-06835-y.
65.
Kanchanatawan B, Sriswasdi S, Thika S, Sirivichayakul S, Carvalho AF, Geffard M, et al. Deficit schizophrenia is a discrete diagnostic cate-gory defined by neuro-immune and neurocognitive features: results of supervised machine learning. Metab Brain Dis 2018; 33: 1053-1067.
66.
Qi H, Zou J, Yao Z, Zhao G, Zhang J, Liu C, Chen M. Differences in EEG complexity of cognitive activities among subtypes of schizophrenia. Front Psychiatry 2025; 16: e1473693. DOI: http://doi.org/10.3389/fpsyt.2025.1473693.
67.
Plichta P, Tyburski E, Bielecki M, Mak M, Kucharska-Mazur J, Podwalski P, et al. Cognitive dysfunctions measured with the MCCB in defi-cit and non-deficit schizophrenia. J Clin Med 2023; 12: e2257. DOI: http://doi.org/10.3390/jcm12062257.
68.
Buchanan RW, Strauss ME, Kirkpatrick B, Holstein C, Breier A, Carpenter WT. Neuropsychological impairments in deficit vs nondeficit forms of schizophrenia. Arch Gen Psychiatry 1994; 51: 804-811.
69.
Horan WP, Blanchard JJ. Neurocognitive, social, and emotional dysfunction in deficit syndrome schizophrenia. Schizophr Res 2003; 65: 125-137.
70.
Wang X, Yao S, Kirkpatrick B, Shi C, Yi J. Psychopathology and neuropsychological impairments in deficit and nondeficit schizophrenia of Chinese origin. Psychiatry Res 2008; 158: 195-205.
71.
Cascella NG, Testa SM, Meyer SM, Rao VA, Diaz-Asper CM, Pearlson GD, Schretlen DJ. Neuropsychological impairment in deficit vs non-deficit schizophrenia. J Psychiatr Res 2008; 42: 930-937.
72.
Gao J, Yu D, Yin M, Li J, Zhang X, Tang X, Zhang X. Distinct white matter abnormalities and cognitive impairments in deficit schizophre-nia: a cross-sectional diffusion tensor imaging study. J Psychiatr Res 2025; 181: 381-390.
73.
Putnam KM, Harvey PD. Cognitive impairment and enduring negative symptoms: a comparative study of geriatric and nongeriatric schiz-ophrenia patients. Schizophr Bull 2000; 26: 867-878.
74.
Zhang L, Zhang X, Fang X, Zhou C, Wen L, Pan X, et al. Eye movement characteristics in male patients with deficit and non-deficit schizo-phrenia and their relationships with psychiatric symptoms and cognitive function. BMC Neurosci 2021; 22: e70. DOI: 10.1186/s12868-021-00673-w.
75.
Brazo P, Marie RM, Halbecq I, Benali K, Segard L, Delamillieure P, et al. Cognitive patterns in subtypes of schizophrenia. Eur Psychiatry 2002; 17: 155-162.
76.
Heckers S, Goff D, Schacter DL, Savage CR, Fischman AJ, Alpert NM, Rauch SL. Functional imaging of memory retrieval in deficit vs non-deficit schizophrenia. Arch Gen Psychiatry 1999; 56: 1117-1123.
77.
Cyran A, Pawlak E, Piotrowski P, Bielawski T, Samochowiec J, Tyburski E, et al. The deficit subtype of schizophrenia is associated with a pro-inflammatory phenotype but not with altered levels of zonulin: findings from a case-control study. Psychoneuroendocrinology 2023; 153: e106109. DOI: http://doi.org/10.1016/j.psyneuen.2023.106109.
78.
Kowalski K, Żebrowska-Różańska P, Karpiński P, Kujawa D, Łaczmański Ł, Samochowiec J, et al. Profiling gut microbiota signatures asso-ciated with the deficit subtype of schizophrenia: findings from a case-control study. Prog Neuropsychopharmacol Biol Psychiatry 2023; 127: e110834. DOI: http://doi.org/10.1016/j.pnpbp.2023.110834.
79.
Pan LH, Qian M, Qu W, Tang Q, Yan Y. Serum C-reactive protein in patients with deficit schizophrenia and the relationship with cognitive function. Neuropsychiatr Dis Treat 2020; 16: 2891-2897.
80.
Wang D, Wang Y, Chen Y, Yu L, Wu Z, Liu R, et al. Differences in inflammatory marker profiles and cognitive functioning between deficit and nondeficit schizophrenia. Front Immunol 2022; 13: e958972. DOI: http://doi.org/10.3389/fimmu.2022.958972.
81.
Bryant JE, Lahti AC, Briend F, Kraguljac NV. White matter neurometabolic signatures support the deficit and nondeficit distinction in anti-psychotic-naive first-episode psychosis patients. Schizophr Bull 2021; 47: 1068-1076.
82.
Samochowiec J, Jabłoński M, Plichta P, Piotrowski P, Stańczykiewicz B, Bielawski T, et al. The self-evaluation of negative symptoms in differentiating deficit schizophrenia: the comparison of sensitivity and specificity with other tools. Psychopathology 2023; 56: 453-461.
83.
Teles M, Maximo JO, Lahti AC, Kraguljac NV. Topological perturbations in the functional connectome support the deficit/non-deficit distinction in antipsychotic medication-naive first episode psychosis patients. Schizophr Bull 2024; 50: 839-847.
84.
Wagman AM, Heinrichs DW, Carpenter WT Jr. Deficit and nondeficit forms of schizophrenia: neuropsychological evaluation. Psychiatry Res 1987; 22: 319-330.
85.
Baddeley A. On applying cognitive psychology. Br J Psychol 2013; 104: 443-456.
86.
Kanchanatawan B, Hemrungrojn S, Thika S, Sirivichayakul S, Ruxrungtham K, Carvalho AF, et al. Changes in tryptophan catabolite (TRYCAT) pathway patterning are associated with mild impairments in declarative memory in schizophrenia and deficits in semantic and episodic memory coupled with increased false-memory creation in deficit schizophrenia. Mol Neurobiol 2018; 55: 5184-5201.
87.
Gao J, Jiang R, Tang X, Chen J, Yu M, Zhou C, et al. A neuromarker for deficit syndrome in schizophrenia from a combination of structural and functional magnetic resonance imaging. CNS Neurosci Ther 2023; 29: 3774-3785.
88.
Gao J, Tang X, Wang C, Yu M, Sha W, Wang X, et al. Aberrant cerebellar neural activity and cerebro-cerebellar functional connectivity involving executive dysfunction in schizophrenia with primary negative symptoms. Brain Imaging Behav 2020; 14: 869-880.
89.
King VL, Lahti AC, Maximo JO, Ver Hoef LW, John S, Kraguljac NV. Contrasting frontoparietal network connectivity in antipsychotic medication-naive first-episode psychosis patients who do and do not display features of the deficit syndrome. Schizophr Bull 2022; 48: 1344-1353.
90.
Ye B, Wu Y, Cao M, Xu C, Zhou C, Zhang X. Altered patterns of dynamic functional connectivity of brain networks in deficit and non-deficit schizophrenia. Eur Arch Psychiatry Clin Neurosci 2025; 275: 743-753.
91.
Al-Hakeim HK, Almulla AF, Maes M. The neuroimmune and neurotoxic fingerprint of major neurocognitive psychosis or deficit schizo-phrenia: a supervised machine learning study. Neurotox Res 2020; 37: 753-771.
92.
Al-Hakeim HK, Al-Musawi AF, Al-Mulla A, Al-Dujaili AH, Debnath M, Maes M. The interleukin-6/interleukin-23/T helper 17-axis as a driver of neuro-immune toxicity in the major neurocognitive psychosis or deficit schizophrenia: a precision nomothetic psychiatry analy-sis. PLoS One 2022; 17: e0275839. DOI: http://doi.org/10.1371/journal.pone.0275839.
93.
Al-Musawi AF, Al-Hakeim HK, Al-Khfaji ZA, Al-Haboby IH, Almulla AF, Stoyanov DS, et al. In schizophrenia, the effects of the IL-6/IL-23/Th17 axis on health-related quality of life and disabilities are partly mediated by generalized cognitive decline and the symptomatome. Int J Environ Res Public Health 2022; 19: e15281. DOI: http://doi.org/10.3390/ijerph192215281.
94.
Maes M, Vojdani A, Sirivichayakul S, Barbosa DS, Kanchanatawan B. Inflammatory and oxidative pathways are new drug targets in multi-ple episode schizophrenia and leaky gut, Klebsiella pneumoniae, and C1q immune complexes are additional drug targets in first episode schizophrenia. Mol Neurobiol 2021; 58: 3319-3334.
95.
Wicklund AH, Johnson N, Rademaker A, Weitner BB, Weintraub S. Word list versus story memory in Alzheimer disease and frontotem-poral dementia. Alzheimer Dis Assoc Disord 2006; 20: 86-92.
96.
Gillouin PA, Mattatia D, Bouvet C. Virtual reality for clinical evaluation and treatment in schizophrenia: a systematic review. Psychosis 2024; 16: 212-229.
97.
Tyburski E, Mak M, Sokołowski A, Starkowska A, Karabanowicz E, Kerestey M, et al. Executive dysfunctions in schizophrenia: a critical review of traditional, ecological, and virtual reality assessments. J Clin Med 2021; 10: e2782. DOI: http://doi.org/10.3390/jcm10132782.
98.
Albus M, Hubmann W, Mohr F, Tiedemann TV, Pechler S, Drießlein D, et al. Neurocognitive functioning in patients with first-episode schizophrenia: results of a prospective 15-year follow-up study. Eur Arch Psychiatry Clin Neurosci 2020; 270: 689-698.
99.
Brébion G, Stephan-Otto C, Huerta-Ramos E, Usall J, Perez Del Olmo M, Contel M, et al. Decreased processing speed might account for working memory span deficit in schizophrenia, and might mediate the associations between working memory span and clinical symptoms. Eur Psychiatry 2014; 29: 473-478.
100.
Brébion G, Stephan-Otto C, Ochoa S, Nieto L, Contel M, Usall J. Verbal fluency in male and female schizophrenia patients: different pat-terns of association with processing speed, working memory span, and clinical symptoms. Neuropsychology 2018; 32: 65-76.
101.
Tyburski EM, Zawadzka E, Bober A, Karabanowicz E, Podwalski P, Samochowiec J, et al. The associations of negative and disorganization symptoms with verbal fluency in schizophrenia: the mediation effect of processing speed and cognitive flexibility. BMC Psychiatry 2025; 25: e282. DOI: http://doi.org/10.1186/s12888-025-06597-7.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). License allowing third parties to download and share its works but not commercially purposes or to create derivative works.
